Effect of PAWI-2 on Pancreatic Cancer Stem Cell Tumors

Overview

Journal Invest New Drugs

Publisher Springer

Specialty Oncology

Date 2024 May 24

PMID 38789849

Authors

John R Cashman

Emily A Cashman

Affiliations

Soon will be listed here.

Abstract

Worldwide, pancreatic cancer (PC) is a major health problem and almost 0.5 million people were diagnosed with PC in 2020. In the United States, more than 64,000 adults will be diagnosed with PC in 2023. PC is highly resistant to currently available treatments and standard of care chemotherapies cause serious side effects. Most PC patients are resistant to clinical therapies. Combination therapy has showed superior efficacy over single-agent treatment. However, most therapy has failed to show a significant improvement in overall survival due to treatment-related toxicity. Developing efficacious clinically useful PC therapies remains a challenge. Herein, we show the efficacy of an innovative pathway modulator, p53-Activator Wnt Inhibitor-2 (PAWI-2) against tumors arising from human pancreatic cancer stem cells (i.e., hPCSCs, FGβ cells). PAWI-2 is a potent inhibitor of tumor growth. In the present study, we showed PAWI-2 potently inhibited growth of tumors from hPCSCs in orthopic xenograft models of both male and female mice. PAWI-2 worked in a non-toxic manner to inhibit tumors. Compared to vehicle-treated animals, PAWI-2 modulated molecular regulators of tumors. Anti-cancer results showed PAWI-2 in vivo efficacy could be correlated to in vitro potency to inhibit FGβ cells. PAWI-2 represents a safe, new approach to combat PC.

Citing Articles

New insights into Notch signaling as a crucial pathway of pancreatic cancer stem cell behavior by chrysin-polylactic acid-based nanocomposite.

Ragab E, El Gamal D, El-Najjar F, Elkomy H, Ragab M, Elantary M Discov Oncol. 2025; 16(1):107.

PMID: 39891818 PMC: 11787125. DOI: 10.1007/s12672-025-01846-3.

References

Rahib L, Smith B, Aizenberg R, Rosenzweig A, Fleshman J, Matrisian L . Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014; 74(11):2913-21. DOI: 10.1158/0008-5472.CAN-14-0155. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2018. CA Cancer J Clin. 2018; 68(1):7-30. DOI: 10.3322/caac.21442. View

Ansari D, Tingstedt B, Andersson B, Holmquist F, Sturesson C, Williamsson C . Pancreatic cancer: yesterday, today and tomorrow. Future Oncol. 2016; 12(16):1929-46. DOI: 10.2217/fon-2016-0010. View

Burris 3rd H, Moore M, Andersen J, Green M, Rothenberg M, Modiano M . Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997; 15(6):2403-13. DOI: 10.1200/JCO.1997.15.6.2403. View

Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y . FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364(19):1817-25. DOI: 10.1056/NEJMoa1011923. View

Jin J, Teng C, Li T . Combination therapy versus gemcitabine monotherapy in the treatment of elderly pancreatic cancer: a meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2018; 12:475-480. PMC: 5846317. DOI: 10.2147/DDDT.S156766. View

Moore M, Goldstein D, Hamm J, Figer A, Hecht J, Gallinger S . Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007; 25(15):1960-6. DOI: 10.1200/JCO.2006.07.9525. View

Spano J, Chodkiewicz C, Maurel J, Wong R, Wasan H, Barone C . Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet. 2008; 371(9630):2101-8. DOI: 10.1016/S0140-6736(08)60661-3. View

Philip P, Benedetti J, Corless C, Wong R, OReilly E, Flynn P . Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol. 2010; 28(22):3605-10. PMC: 2917315. DOI: 10.1200/JCO.2009.25.7550. View

10.

Kreso A, Dick J . Evolution of the cancer stem cell model. Cell Stem Cell. 2014; 14(3):275-91. DOI: 10.1016/j.stem.2014.02.006. View

11.

Nassar D, Blanpain C . Cancer Stem Cells: Basic Concepts and Therapeutic Implications. Annu Rev Pathol. 2016; 11:47-76. DOI: 10.1146/annurev-pathol-012615-044438. View

12.

Dean M, Fojo T, Bates S . Tumour stem cells and drug resistance. Nat Rev Cancer. 2005; 5(4):275-84. DOI: 10.1038/nrc1590. View

13.

Hermann P, Huber S, Herrler T, Aicher A, Ellwart J, Guba M . Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2008; 1(3):313-23. DOI: 10.1016/j.stem.2007.06.002. View

14.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

15.

Meacham C, Morrison S . Tumour heterogeneity and cancer cell plasticity. Nature. 2013; 501(7467):328-37. PMC: 4521623. DOI: 10.1038/nature12624. View

16.

Bivona T, Hieronymus H, Parker J, Chang K, Taron M, Rosell R . FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR. Nature. 2011; 471(7339):523-6. PMC: 3541675. DOI: 10.1038/nature09870. View

17.

Seguin L, Kato S, Franovic A, Camargo M, Lesperance J, Elliott K . An integrin β₃-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition. Nat Cell Biol. 2014; 16(5):457-68. PMC: 4105198. DOI: 10.1038/ncb2953. View

18.

Desgrosellier J, Barnes L, Shields D, Huang M, Lau S, Prevost N . An integrin alpha(v)beta(3)-c-Src oncogenic unit promotes anchorage-independence and tumor progression. Nat Med. 2009; 15(10):1163-9. PMC: 2759406. DOI: 10.1038/nm.2009. View

19.

Seguin L, Camargo M, Wettersten H, Kato S, Desgrosellier J, Von Schalscha T . Galectin-3, a Druggable Vulnerability for KRAS-Addicted Cancers. Cancer Discov. 2017; 7(12):1464-1479. PMC: 5718959. DOI: 10.1158/2159-8290.CD-17-0539. View

20.

Desgrosellier J, Cheresh D . Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2009; 10(1):9-22. PMC: 4383089. DOI: 10.1038/nrc2748. View